MedTrace Logo

The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)

NCT02767401 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-03-19

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of percutaneous coronary intervention (PCI) on myocardial viability in coronary artery disease patients with single coronary total occlusion (CTO) lesions.

Conditions

  • Hibernation, Myocardial
  • Complete Occlusion of Coronary Artery

Interventions

DEVICE

stenting or balloon expansion

all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)

DRUG

aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc

Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    collaborator OTHER

  • First Hospital of China Medical University

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • The First Affiliated Hospital of Dalian Medical University

    lead OTHER

Principal Investigators

  • Rongchong Huang, M.D. · The First Affiliated Hospital of Dalian Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-15
Primary Completion
2018-08-15
Completion
2018-12-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02767401 on ClinicalTrials.gov